Manmohan Singh

List of Publications by Year
in descending order

91 papers	7,343 citations	47 h-index	84 g-index
		47006	54911
95 all docs	95 docs citations	95 times ranked	6935 citing authors

#	Article	IF	Citations
1	The Preparation and Physicochemical Characterization of Aluminum Hydroxide/TLR7a, a Novel Vaccine Adjuvant Comprising a Small Molecule Adsorbed to Aluminum Hydroxide. Journal of Pharmaceutical Sciences, 2018, 107, 1577-1585.	3.3	10
2	Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators. Journal of Pharmaceutical Sciences, 2018, 107, 2310-2314.	3.3	9
3	Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Advances, 2017, 1, 2329-2342.	5.2	90
4	Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide. Journal of Medicinal Chemistry, 2016, 59, 5868-5878.	6.4	38
5	The Development of Self-Emulsifying Oil-in-Water Emulsion Adjuvant and an Evaluation of the Impact of Droplet Size on Performance. Journal of Pharmaceutical Sciences, 2015, 104, 1352-1361.	3.3	39
6	Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. Nature Communications, 2015, 6, 6565.	12.8	77
7	Rational design of small molecules as vaccine adjuvants. Science Translational Medicine, 2014, 6, 263ra160.	12.4	153
8	Physicochemical and functional characterization of vaccine antigens and adjuvants. Expert Review of Vaccines, 2014, 13, 671-685.	4.4	40
9	A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines. Molecular Therapy, 2014, 22, 2118-2129.	8.2	255
10	Preparation of Highly Concentrated Influenza Vaccine for Use in Novel Delivery Approaches. Journal of Pharmaceutical Sciences, 2013, 102, 866-875.	3.3	9
11	MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. Human Vaccines and Immunotherapeutics, 2012, 8, 486-490.	3.3	34
12	Nonviral delivery of self-amplifying RNA vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14604-14609.	7.1	498
13	The vaccine adjuvant alum inhibits <scp>IL</scp>â€12 by promoting <scp>PI</scp>3 kinase signaling while chitosan does not inhibit <scp>IL</scp>â€12 and enhances <scp>T</scp>h1 and <scp>T</scp>h17 responses. European Journal of Immunology, 2012, 42, 2709-2719.	2.9	124
14	Aluminum Adjuvant Dose Guidelines in Vaccine Formulation for Preclinical Evaluations. Journal of Pharmaceutical Sciences, 2012, 101, 17-20.	3.3	43
15	Dissolvable Microneedle Patches for the Delivery of Cell-Culture-Derived Influenza Vaccine Antigens. Journal of Pharmaceutical Sciences, 2012, 101, 1021-1027.	3.3	97
16	The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Review of Vaccines, 2011, 10, 1731-1742.	4.4	101
17	An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine, 2011, 29, 6262-6268.	3.8	32
18	Flow cytometry: An alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant. Analytical Biochemistry, 2011, 418, 224-230.	2.4	33

#	Article	IF	Citations
19	COMMENTARY: Acceptable Levels of Endotoxin in Vaccine Formulations During Preclinical Research. Journal of Pharmaceutical Sciences, 2011, 100, 34-37.	3.3	145
20	A Two-Stage Strategy for Sterilization of Poly(lactide-co-glycolide) Particles by Î³-Irradiation Does Not Impair Their Potency for Vaccine Delivery. Journal of Pharmaceutical Sciences, 2011, 100, 646-654.	3.3	19
21	Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminumâ€containing adjuvants on the immune response. Journal of Pharmaceutical Sciences, 2011, 100, 3245-3250.	3.3	28
22	Combination vaccines. Journal of Global Infectious Diseases, 2011, 3, 63.	0.5	95
23	Micro/Nanoparticle Adjuvants: Preparation and Formulation with Antigens. Methods in Molecular Biology, 2010, 626, 91-101.	0.9	16
24	MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020). Pharmaceutical Research, 2009, 26, 1477-1485.	3.5	80
25	Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Advanced Drug Delivery Reviews, 2009, 61, 218-225.	13.7	79
26	Variation of indoor radon progeny concentration and its role in dose assessment. Journal of Environmental Radioactivity, 2008, 99, 539-545.	1.7	18
27	Characterization of antigens adsorbed to anionic PLG microparticles by XPS and TOFâ€SIMS. Journal of Pharmaceutical Sciences, 2008, 97, 1443-1453.	3.3	20
28	The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. Journal of Pharmaceutical Sciences, 2008, 97, 1155-1164.	3.3	48
29	Endotoxin Limits in Formulations for Preclinical Research. Journal of Pharmaceutical Sciences, 2008, 97, 2041-2044.	3.3	161
30	Î²7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology, 2008, 123, 378-389.	4.4	21
31	Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine, 2008, 26, 552-561.	3.8	166
32	Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination. Vaccine, 2008, 26, 753-761.	3.8	19
33	Dose-Dependent Protection against or Exacerbation of Disease by a Polylactide Glycolide Microparticle-Adsorbed, Alphavirus-Based Measles Virus DNA Vaccine in Rhesus Macaques. Vaccine Journal, 2008, 15, 697-706.	3.1	26
34	A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccin, 2008, 4, 44-49.	2.4	76
35	Formulations and Delivery Systems for Mucosal Vaccines. , 2008, , 499-511.		2
36	Nanoparticles and microparticles as vaccine-delivery systems. Expert Review of Vaccines, 2007, 6, 797-808.	4.4	232

#	Article	IF	Citations
37	Protection of Rhesus Monkeys by a DNA Prime/Poxvirus Boost Malaria Vaccine Depends on Optimal DNA Priming and Inclusion of Blood Stage Antigens. PLoS ONE, 2007, 2, e1063.	2.5	30
38	Extent of Supercoiling in Plasmid DNA Vaccines. American Journal of Drug Delivery, 2006, 4, 195-199.	0.6	0
39	Intranasal delivery of vaccines against HIV. Expert Opinion on Drug Delivery, 2006, 3, 247-259.	5.0	21
40	Microparticle-based technologies for vaccines. Methods, 2006, 40, 10-19.	3.8	155
41	A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine, 2006, 24, 1680-1686.	3.8	79
42	A modified process for preparing cationic polylactide-co-glycolide microparticles with adsorbed DNA. International Journal of Pharmaceutics, 2006, 327, 1-5.	5.2	23
43	Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. Journal of Controlled Release, 2006, 110, 566-573.	9.9	109
44	A Practical Approach to the use of Nanoparticles for Vaccine Delivery. Journal of Pharmaceutical Sciences, 2006, 95, 2738-2750.	3.3	82
45	Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. Journal of General Virology, 2006, 87, 2253-2262.	2.9	45
46	Polylactide-Co-Glycolide Microparticles with Surface Adsorbed Antigens as Vaccine Delivery Systems. Current Drug Delivery, 2006, 3, 115-120.	1.6	63
47	Nanoparticles and Microparticles as Vaccine Adjuvants. , 2006, , 675-696.		2
48	Microparticles and DNA Vaccines. , 2006, , 257-270.		0
49	An Investigation of the Factors Controlling the Adsorption of Protein Antigens to Anionic PLG Microparticles. Journal of Pharmaceutical Sciences, 2005, 94, 2510-2519.	3.3	48
50	Variation of radon (Rn) progeny concentrations in outdoor air as a function of time, temperature and relative humidity. Radiation Measurements, 2005, 39, 213-217.	1.4	47
51	CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine. Infection and Immunity, 2005, 73, 828-833.	2.2	117
52	Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins. Journal of Virology, 2005, 79, 8189-8200.	3.4	75
53	The role of adjuvants in the development of mucosal vaccines. Expert Opinion on Biological Therapy, 2005, 5, 953-965.	3.1	24
54	DNA Vaccines. Pharmaceutical Medicine, 2005, 19, 15-28.	0.4	7

#	Article	IF	Citations
55	Mucosal and Systemic Anti-HIV Responses in Rhesus Macaques following Combinations of Intranasal and Parenteral Immunizations. AIDS Research and Human Retroviruses, 2004, 20, 1269-1281.	1.1	60
56	Mucosal adjuvants and delivery systems for proteinâ€, DNAâ€•and RNAâ€based vaccines. Immunology and Cell Biology, 2004, 82, 617-627.	2.3	91
57	Microparticles for the delivery of DNA vaccines. Immunological Reviews, 2004, 199, 191-200.	6.0	132
58	Adsorption of a Novel Recombinant Glycoprotein from HIV (Env gp120dV2 SF162) to Anionic PLG Microparticles Retains the Structural Integrity of the Protein, Whereas Encapsulation in PLG Microparticles Does Not. Pharmaceutical Research, 2004, 21, 2148-2152.	3.5	49
59	Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. Journal of Pharmaceutical Sciences, 2004, 93, 273-282.	3.3	64
60	Charged polylactide co-glycolide microparticles as antigen delivery systems. Expert Opinion on Biological Therapy, 2004, 4, 483-491.	3.1	48
61	Maintenance of long-term immunological memory by low avidity IgM-secreting cells in bone marrow after mucosal immunizations with cholera toxin adjuvant. Vaccine, 2004, 22, 1553-1563.	3.8	20
62	Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine, 2004, 22, 2690-2695.	3.8	47
63	Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine, 2004, 23, 672-680.	3.8	70
64	Cationic Microparticles and Emulsions As Effective Delivery Systems for Immune Stimulatory CpG DNA. , 2004, , 265-276.		0
65	The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance. Pharmaceutical Research, 2003, 20, 247-251.	3.5	48
66	Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cellular Immunology, 2003, 225, 12-20.	3.0	83
67	Recent advances in veterinary vaccine adjuvants. International Journal for Parasitology, 2003, 33, 469-478.	3.1	155
68	Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology, 2003, 110, 86-94.	4.4	57
69	Microparticles as vaccine adjuvants and delivery systems. Expert Review of Vaccines, 2003, 2, 269-283.	4.4	205
70	Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles. Journal of Virology, 2003, 77, 6087-6092.	3.4	67
71	Advances in Vaccine Adjuvants For Infectious Diseases. Current HIV Research, 2003, 1, 309-320.	0.5	36
72	A cationic sub-micron emulsion (MF59/DOTAP) is an effective delivery system for DNA vaccines. Journal of Controlled Release, 2002, 79, 1-5.	9.9	73

#	Article	IF	Citations
73	Recent advances in vaccine adjuvants. Pharmaceutical Research, 2002, 19, 715-728.	3.5	211
74	Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine, 2001, 20, 594-602.	3.8	71
75	Recent developments in adjuvants for vaccines against infectious diseases. New Biotechnology, 2001, 18, 69-85.	2.7	300
76	Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharmaceutical Research, 2001, 18, 1476-1479.	3.5	104
77	A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. Journal of Controlled Release, 2001, 70, 267-276.	9.9	127
78	Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines. Journal of Virology, 2001, 75, 9037-9043.	3.4	186
79	Advances in vaccine adjuvants. Nature Biotechnology, 1999, 17, 1075-1081.	17.5	456
80	Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Advanced Drug Delivery Reviews, 1998, 32, 225-246.	13.7	216
81	Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models. Vaccine, 1998, 16, 346-352.	3.8	47
82	Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine, 1997, 15, 475-481.	3.8	79
83	Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine, 1996, 14, 1523-1530.	3.8	121
84	Biodegradable delivery system for a birth control vaccine: immunogenicity studies in rats and monkeys. Pharmaceutical Research, 1995, 12, 1796-1800.	3.5	38
85	Biodegradable delivery system for single step immunization with tetanus toxoid. International Journal of Pharmaceutics, 1993, 93, R1-R5.	5.2	45
86	A Birth Control Vaccine is on the Horizon for Family Planning. Annals of Medicine, 1993, 25, 207-212.	3.8	15
87	Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres. International Journal of Pharmaceutics, 1992, 85, R5-R8.	5.2	31
88	Controlled delivery of diphtheria toxoid using biodegradable poly(D,L-lactide) microcapsules. Pharmaceutical Research, 1991, 08, 958-961.	3.5	86
89	Controlled release of LHRH-DT from bioerodible hydrogel microspheres. International Journal of Pharmaceutics, 1991, 76, R5-R8.	5.2	33
90	Surface-Charged Poly(Lactide-Co-Glycolide) Microparticles as Novel Antigen Delivery Systems. , 0, , 223-247.		3

#	Article	IF	Citations
91	MF59: A Safe and Potent Oil-in-Water Emulsion Adjuvant. , 0, , 115-129.		5